IGF2BP2 and cancer: Our data thus argue that targeting IGF2BP2 likely produces an SDL effect in PLK1-overexpressing cancer cells by reducing PLK1 expression and its associated activities, while simultaneously decreasing the stability of mitochondrial transcripts encoding core OXPHOS subunits; a synergistic effect that greatly reduces the capacity to generate ATP (Figure 5I).